Interferon Type I

Subscribe to Selected New Research on Interferon Type I

688 relevant articles (15 outcomes, 50 trials/studies) found for this Bio-Agent

Description: Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).

Also Known As:

Interferons Type I; Type I Interferon; Type I Interferons; Interferon, Type I; Interferons, Type I

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Experts

1.	Alm, Gunnar V: 5 articles (09/2007 - 01/2003)
2.	Rönnblom, Lars: 5 articles (09/2007 - 01/2003)
3.	Belardelli, Filippo: 4 articles (04/2008 - 04/2002)
4.	Wenzel, Joerg: 4 articles (12/2007 - 03/2005)
5.	Tüting, Thomas: 4 articles (12/2007 - 03/2005)
6.	Alsharifi, Mohammed: 3 articles (03/2008 - 10/2005)
7.	Müllbacher, Arno: 3 articles (03/2008 - 10/2005)
8.	Regner, Matthias: 3 articles (03/2008 - 10/2005)
9.	Bieber, Thomas: 3 articles (12/2007 - 03/2005)
10.	Zhuang, Haoyang: 3 articles (11/2007 - 12/2005)

Related Diseases

1.	Infection 04/25/1999 - "Thus, type I interferon, as well as IRF-1 and IRF-2, appears to play an important and necessary role in the pathogenesis of, and protection against, VEE infection." 10/01/2002 - "Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection." 09/01/2009 - "In this study we show that an intact type I interferon system and the adaptive immune responses are required for controlling MHV-1 replication and preventing morbidity and mortality in resistant C57BL/6J mice after infection. " 04/10/2009 - "Previous studies implicated the type I interferon (IFN) response as being a major factor in controlling infection by apathogenic isolates. " 01/01/2009 - "No noticeable and consistent effect was observed following engagement of TLR5, 7 and 9. Additional studies indicated that both HIV-1 infection of DCs and DC-mediated virus transmission to CD4+ T cells were reduced upon TLR4 triggering due to secretion of type-I interferons. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/2001 - "Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. " 02/01/1996 - "We have used the monoclonal antibody IFNaR3 that recognizes the alpha subunit of the type I interferon (IFN) receptor to study the expression of this receptor in a large series of normal human adult and fetal tissues, as well as in a large number of tumors of diverse origin. " 05/21/2009 - "We further showed that CpG-induced type I interferon was critical for the reversal of tumor-specific tolerance in vivo. " 02/01/2009 - "Type I interferons contributed significantly to the combined anti-tumor activity." 02/01/2009 - "The anti-tumor activity of the combination therapy was significantly impaired when the type I interferons in the mice were neutralized. " Order ALL the reference details at left...
3.	Multiple Sclerosis 01/01/2004 - "Multiple sclerosis (MS) patients treated with type I interferon experience reduced disease activity. " 11/11/2003 - "Carefully conducted large-scale clinical trials have provided strong evidence that type I interferons favorably influence clinical and MRI outcomes in patients with multiple sclerosis. " 06/01/2008 - "Type I Interferon (IFN-alpha/beta) therapy has altered the natural course of multiple sclerosis. " 06/01/2008 - "Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients." 03/20/2006 - "We determined NAB status in Australasian multiple sclerosis patients receiving IFNbetausing both the antiviral cytopathic effect (CPE) assay (n = 227) and the more specific ELISA for the type I interferon-inducible MxA protein (n = 350). " Order ALL the reference details at left...
4.	Glioma (Gliomas) 06/15/1994 - "Deletions of the 9p-localized type-I interferon (IFN) genes and adjacent loci often occur during the development of malignant glioma. " 11/01/2004 - "Because glioma cells undergo apoptosis after transfection with the type I interferon (IFN) gene and type I IFNs promote the stimulatory activity of DCs, we hypothesized that transfection of glioma cells with type I IFN genes and provision of DCs would promote particularly effective antitumor activity by both facilitating apoptosis of glioma cells and the presentation of the glioma antigens, thereby inducing specific immune responses against glioma cells. " 07/01/2003 - "As type I interferons (IFNs) enhance the stimulatory activity of dendritic cells (DCs), we hypothesized that transfection of glioma cells with the IFN-beta gene in the presence of DCs would provide particularly effective antitumor activity by both facilitating apoptosis of glioma cells and presenting the resulting glioma antigens to T cell by DCs, thereby inducing specific T-cell responses against glioma cells. " 08/15/1993 - "Southern blot analyses of the 9p-localized type I interferon (IFN) genes in DNAs obtained from malignant glioma cell lines and glial tumor tissue have indicated that homozygous deletions of the IFN-alpha and IFN-beta genes often occur during the development of the highly malignant central nervous system neoplasm, glioblastoma. " 02/01/2002 - "Double-stranded RNA decreases IGF-I gene expression in a protein kinase R-dependent, but type I interferon-independent, mechanism in C6 rat glioma cells." Order ALL the reference details at left...
5.	Vaccinia 10/25/2005 - "Collectively, our data define a new function for type I interferon signaling in systemic dissemination of vaccinia and validate these reporter viruses for studies of pathogenesis." 10/25/2005 - "Replication of vaccinia was significantly greater in mice lacking receptors for type I interferons (IFN I R-/-) compared with wild-type mice, although both genotypes of mice developed focal infections in lungs and brain after intranasal inoculation. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Interferon-beta
2.	Antigens
3.	Interferon-alpha (Interferon Alfa)
4.	Proteins (Proteins, Gene)
5.	Interferon Regulatory Factors
6.	Messenger RNA (mRNA)
7.	VBA protocol
8.	Interferons
9.	Cytokines
10.	Toll-Like Receptors (Toll-Like Receptor)

Related Therapies and Procedures

1.	Oral Administration
2.	Intraperitoneal Injections
3.	Heterologous Transplantation (Xenotransplantation)
4.	Therapeutics
5.	Remission Induction

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>